The extract is commonly used across domains where additional symptomatic support is needed, primarily focusing on conditions involving symptoms related to chronic inflammatory or irritative states. It is relevant in clinical settings marked by heightened patient distress, applied to help ease challenging symptoms and support patient comfort. It is used in situations involving certain distressing symptoms, such as those related to gastric ulcers, chronic burns, and mucosal injury.

Support for Chronic Wound Healing and Tissue Regeneration

This domain is relevant when symptoms that create noticeable physiological strain cluster into patterns of non-healing tissue defects, such as severe burns or chronic pressure ulcers. It is applied in contexts where additional management of discomfort is required, providing supportive relief that may assist with tissue repair and regeneration and contributes to helping ease the overall symptom load.

“It is relevant in contexts marked by increased discomfort, providing supportive relief when symptoms interfere with routine activities.”

Symptomatic Relief for Internal Ulcers and Mucosal Distress

The medicine is commonly used across conditions characterized by erosion and ulceration of the digestive tract lining, including gastric and duodenal ulcers. It helps address groups of symptoms that may become disruptive, offering symptomatic relief that helps ease the overall symptom load and may assist with maintaining comfort during symptomatic periods.

Management of Oral Pain and Chemotherapy-Induced Injury

Applied in clinical settings that involve acute or unstable symptom patterns, particularly the pain and severe ulceration of the oral lining seen in recurrent oral ulcers and mucositis in oncology patients. It is used when symptoms become more disruptive during flare-ups, offering symptomatic support that helps ease the overall symptom burden.

---

Quick Fact: Relief for Non-healing Tissue Defects

Population Eligibility and Regulatory Restrictions

The use of the complex biologic extract derived from the American Cockroach is strictly defined by official regulatory eligibility criteria. Based on available data, use is established for the Adult Population (aged 18 years and older).

Absolute Contraindications

The medicine is formally contraindicated for several populations. These include individuals with known hypersensitivity or allergy to the medicine's components. Use is strictly prohibited in patients experiencing acute complications such as Gastric Perforation or active internal bleeding (Gastrorrhagia). For external application, use is also contraindicated in the presence of local skin ulcers, infections, or bleeding tendencies.

Restricted and Excluded Populations

Use is not recommended or restricted for patients with severe Hepatic or Renal dysfunction and those with Systemic Chronic Inflammatory Diseases or Coagulation Dysfunction. Furthermore, use is not established and therefore not recommended in the Pediatric Population (under 18) due to insufficient safety and efficacy data. The medicine is also excluded from use in pregnant women and nursing mothers.

Interactions with other medicines and products

The official regulatory profile for the medicinal product derived from the American Cockroach focuses on a specific pharmacodynamic constraint rather than classical metabolic interactions.

Interaction Scope

Category	Official Regulatory Information
Medicinal product categories with documented interactions	Beta-blockers (all classes)
Specific interacting medicines	Epinephrine, Inhaled Bronchodilators
Mechanistic basis of interactions	Pharmacodynamic interaction related to compromised systemic response to emergency treatment.
Timing-based interaction rules	None formally documented in regulatory labels.
Population-specific interaction notes	Patients receiving Beta-blockers
Interaction-related restrictions	Restriction on co-administration due to the compromise of emergency management following a severe adverse reaction.

Interaction Classifications

Category	Official Regulatory Information
Interaction severity classification	A clinically significant pharmacodynamic restriction related to emergency preparedness.
Regulatory basis	US Food and Drug Administration (FDA)
Interaction-context constraints	Relevant only in the context of managing a severe systemic adverse reaction to the product.

Resulting Interaction Structure

The regulatory documentation states that patients receiving beta-blockers may be unresponsive to epinephrine and inhaled bronchodilators in the event of a severe systemic adverse reaction. No formal statements regarding pharmacokinetic (CYP, transporter) interactions or food/alcohol interactions are included in the official regulatory prescribing information for this product. The official profile is therefore defined by a singular, critical co-administration restriction tied to emergency procedure, rather than routine drug-metabolism patterns.

The mechanism of action of the Periplaneta americana extract is defined by its function as a complex biological modulator that executes a dual strategy: simultaneously suppressing inflammatory responses and influencing pathways associated with cellular remodeling.

Suppression of Pro-Inflammatory Cascades

The extract targets the NF-kappaB signaling pathway, a central regulator of inflammation, acting as an inhibitor to limit its activation. By reducing the transcription and release of major pro-inflammatory cytokines (like TNF-alpha and IL-1beta), the mechanism results in the modulation of signaling that contributes to physiological vascular changes and fluid dynamics.

Activation of Tissue Formation and Cellular Growth

The mechanism influences signaling pathways associated with tissue formation by serving as an activator of key growth signals, including the ERK and Wnt/beta-catenin pathways. This action enhances the proliferation and directed migration of epithelial cells and fibroblasts, thereby leading to the enhancement of cellular processes that facilitate tissue approximation and barrier integrity.

Synergy and Antioxidant System Enhancement

The complex blend of peptides and other bioactive molecules results in a complementary and coordinated mechanistic influence. This includes the modulation of the body's antioxidant defenses (upregulating enzymes like SOD), which supports the reduction of reactive oxygen species and modulates the microenvironment essential for cellular reconstruction.

The medicinal product derived from the American Cockroach (Periplaneta americana) is an extract used in specific administration patterns. The product is administered through two primary approaches: oral ingestion for internal conditions, and topical or local application for external tissue defects.

For oral use, the liquid solution is typically dosed for adults at 10 milliliters (mL) per time, resulting in a usual daily total of 30 mL when administered three times per day. The solution may be taken undiluted or mixed with warm water, depending on the specific protocol.

A specialized administration technique is required when the product is used for mucosal lesions in the oral cavity. In this context, the measured dose is first used to rinse the affected area for a prescribed duration before being slowly swallowed, a procedural step intended to ensure adequate contact with the target tissue.

For external applications, such as chronic wounds or pressure ulcers, the extract is applied directly to the affected area or utilized via saturated dressings. The frequency of topical use can range from once daily to multiple times daily, generally correlating with the required wound dressing changes. Regardless of the route, the medicine is used in finite, time-limited courses, with treatment durations varying but often lasting from 7 to 45 days, rather than as part of a continuous long-term plan. This structured approach defines the standardized administration of the medicine.

Evidence for use in Chronic Wound Healing

The type of research with the highest level of human evidence available for this area includes meta-analyses that aggregate data from multiple existing Randomized Controlled Trials (RCTs) involving adult patients with chronic non-healing ulcers, such as diabetic skin ulcers. The extract was evaluated in research exploring outcomes related to tissue repair. These studies primarily focused on the measurement of outcomes such as the primary outcome success rate and the time intervals observed for re-epithelialization.

It is important to note that this research is heavily concentrated within a specific geographic and regulatory context. While the existence of multiple RCTs suggests a moderate level of evidence, the methodological quality of all individual trials summarized is not consistently assessed or explicitly reported, meaning certainty remains low regarding the global consistency of findings.

---

Evidence for use in Internal and Oral Mucosal Injuries

The level of human clinical data available is different for internal conditions, such as gastric ulcers, and for localized injuries, such as oral ulcers. Here, the evidence primarily comes from pre-clinical studies that use animal models (in vivo) and laboratory studies focusing on activity at the cellular and molecular level. The extract was evaluated in research exploring how symptoms linked to inflammatory or irritative states were measured in pre-clinical models. There is a general scarcity of published, high-quality Randomized Controlled Trials (RCTs) in human subjects for these specific indications, which means certainty remains low regarding clinical application.

---

Long-Term Studies and Follow-up

The available research provides limited information on the extended effects of the extract. The observation periods in clinical trials related to wound healing are typically classified as intermediate-term, spanning several weeks. Pre-clinical studies focus on research exploring short-term symptom changes over days. Consequently, long-term effects are not fully established, and the long-term consistency of short-term study measurements related to wounds or ulcers is uncertain.

---

Evidence in Specific Patient Groups

Clinical research for the extract has monitored outcomes in adult patients with specific comorbidities, such as those with diabetic foot ulcers. The results apply only to the populations studied and do not provide sufficient evidence for other patient groups. Data for certain groups remain insufficient. For instance, there is limited information for children, older adults, or populations related to pregnancy.

---

What is Still Uncertain about American Cockroach Research

Research highlights what is known—and what is still uncertain—about this extract. A key research limitation is the evidence quality varies across studies, especially the heavy reliance on pre-clinical data for internal and oral mucosal conditions, where sample sizes were modest in the initial human trials. Comparative evidence is lacking for many traditional uses, and subgroup findings are uncertain.

Common questions about American Cockroach (FAQ)

Q: What is the difference between the active ingredient and the inactive ingredients in the tablets?

According to the official product information, the active ingredient is defined as a complex blend of natural proteins and bioactive peptides derived from the American Cockroach extract. This substance is responsible for the medicine’s therapeutic activity. The product also contains inactive ingredients, which typically include compounds such as ethanol, propylene glycol, and polysorbate.

Q: What are the most commonly reported side effects of American Cockroach?

Studies monitoring adverse events associated with this product indicate a generally low overall incidence of reactions. The non-allergic reactions that have been noted in these clinical trials include symptoms such as fatigue, dizziness, nausea, and headache. It is important to review the complete official safety information for a full overview of possible adverse effects.

Q: What is the risk of having a serious allergic reaction to American Cockroach?

As a complex biologic agent, the primary safety concern described in regulatory documents is the potential for an IgE-mediated allergic reaction, which can be severe. While the overall adverse event rates monitored in studies are generally low, official regulatory information for this extract does not provide a formal frequency classification (such as 'rare' or 'common') for severe systemic allergic reactions.

Q: Is it normal to feel a little dizzy or drowsy after taking American Cockroach?

Clinical studies monitoring the use of the extract have noted that some subjects experienced instances of dizziness and fatigue or drowsiness. These symptoms are included in the documented adverse events observed in research settings.

Q: Does American Cockroach affect your sleep patterns?

Clinical studies monitoring adverse reactions have noted instances of fatigue and drowsiness in some subjects. Fatigue and drowsiness are among the documented adverse events, which are known to be related to alertness.

Q: Why do some people experience headaches or mild nausea when they first start taking American Cockroach?

Research and safety monitoring of the product have documented instances of both headache and nausea as reported adverse reactions. Official documents describe these as known potential effects that some individuals may experience.

Q: What is the legal or approval status of American Cockroach in other major countries?

The product is primarily regulated and approved for widespread use within the People's Republic of China, operating under the National Medical Products Administration (NMPA) framework. Its regulatory status in other major global regions, such as North America and Europe, is often not fully established. Therefore, use is most commonly cited within the specific regulatory context of China.

How to Store and Dispose of American Cockroach Extract

The official regulatory storage profile for the Periplaneta americana extract (a natural biologic agent) is governed by specific conditions to maintain product stability.

Storage & Disposal Scope	Official Regulatory Requirement
Labeled Storage Temperature	Store the product in a cool place, below 30 C, and avoid high temperatures.
Light/Moisture Protection	Product must be protected from light and maintained in a dry environment.
Packaging Storage Rules	The medicine must be kept in its original container with the cap tightly closed when not in use.
Child-Protection Storage	It is mandatory to store the medicine out of the sight and reach of children.
Official Disposal Rules	Dispose of any unused or expired extract according to local pharmaceutical waste regulations; do not discard with household trash or down the drain.